pyrroles has been researched along with Hypertension in 347 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (3.46) | 18.7374 |
| 1990's | 20 (5.76) | 18.2507 |
| 2000's | 155 (44.67) | 29.6817 |
| 2010's | 146 (42.07) | 24.3611 |
| 2020's | 14 (4.03) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S; Itoh, H; Kario, K; Okuda, Y; Rakugi, H; Yamakawa, S | 1 |
| Iwahana, T; Kato, H; Kobayashi, Y; Okada, S; Ono, R; Saito, Y | 1 |
| Ichihara, A; Morimoto, S | 1 |
| Ichikawa, S; Sugimoto, K; Tsutsumi, J; Yamakawa, S | 1 |
| Akasaka, T; Hashimoto, M; Hosoya, T; Komoto, K; Murakami, K; Nakajima, H; Nakamura, A; Nunoue, T; Shiosakai, K; Sugimoto, K; Taguchi, T; Uchida, HA; Wada, J | 1 |
| Hanada, K; Itoh, K; Kato, T; Kawamura, Y; Kitayama, K; Kudo, N; Miura, N; Nakata, M; Narita, M; Nozaka, M; Tatara, Y; Tomita, H; Toyama, Y; Tsushima, M; Yokono, Y | 1 |
| Fischer, T; Inoue, SI; Ishizuka, T; Rozehnal, V; Sugiyama, D; Yamada, M | 1 |
| Nishiyama, A; Rahman, A; Wan, N | 1 |
| Homma, T; Igawa, Y; Yamada, M; Yamakawa, S; Yoshimura, M | 1 |
| Ito, S; Itoh, H; Kario, K; Okuda, Y; Rakugi, H; Yamakawa, S; Yoshimura, M | 1 |
| Rakugi, H; Sugimoto, K; Yamakawa, S | 1 |
| Ako, J; Fujita, T; Fukaya, H; Ikeda, Y; Ishii, S; Kawaguchi, T; Maemura, K; Minami, Y; Nabeta, T; Naruke, T; Oki, T; Shimohama, T; Yazaki, M; Yuge, M | 1 |
| Hossain, A; Imamura, T; Jahan, N; Kitada, K; Kobara, H; Kosaka, S; Masaki, T; Nakano, D; Nishiyama, A; Ohsaki, H; Rahman, A; Sawano, T; Sen, A | 1 |
| Aguirre, JI; Aronovitz, MJ; Baca, P; Baumgartner, RA; Blanton, RM; Calamaras, TD; Davis, RJ; Jaffe, IZ; Karas, RH; Kim, SK; Lin, W; Liu, P; Martin, GL; McCarthy, JC; McLaughlin, AL; Pande, S; Richards, DA; Tam, K; Wang, GR | 1 |
| Danser, AH; Lankhorst, S; Markó, L; Müller, DN; Rakova, N; Severs, D; Titze, J; van den Meiracker, AH | 1 |
| Buckley, NA; Pearson, SA; Schaffer, AL | 1 |
| Bai, Y; Chen, X; He, X; Liu, P; Sun, Y; Zhao, Z; Zheng, X | 1 |
| Guan, Y; Kobara, H; Kobori, H; Li, L; Masaki, T; Morishita, A; Nakano, D; Nishiyama, A | 1 |
| Duggan, S | 1 |
| Furuie, H; Ishizuka, H; Ishizuka, T; Kato, M; Kurata, A; Nakatsu, T; Nishikawa, Y; Shimizu, T | 1 |
| Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Tziolas, IM; Zebekakis, PE | 1 |
| Hradec, J; Sutradhar, S; Zamorano, J | 1 |
| Amini, R; Jahanbakhsh, Z; Mohammadi, MT; Shekarforoush, S | 1 |
| Ivanovic, B; Tadic, M | 1 |
| Andersson, O; Bergh, N; Grote, L; Hrafnkelsdóttir, TJ; Saluveer, O; Widgren, BR | 1 |
| Chang, CL; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Arican, N; Gelisgen, R; Kalayci, R; Kaya, M; Konukoglu, D; Sozer, V; Tabak, O; Uzun, H | 1 |
| Chang, C; Chen, X; Jiang, H; Lou, D; Qin, Q; Wang, J; Zhang, W; Zhong, D; Zhou, A | 1 |
| Guo, F; Han, W; Li, JX; Li, YD; Tang, BP; Tang, Q; Zhang, YY | 1 |
| Anzini, M; Biava, M; Breschi, MC; Calderone, V; Cappelli, A; Caselli, G; Consalvi, S; Di Capua, A; Ghelardini, C; Giordani, A; Martelli, A; Patrignani, P; Poce, G; Rovati, L; Sautebin, L; Testai, L | 1 |
| Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI | 1 |
| Takagi, H; Umemoto, T | 1 |
| Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E | 1 |
| Bangalore, S; Deedwania, P; Demicco, DA; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Arakawa-Todo, M; Hasegawa, T; Kajikawa, K; Kato, Y; Kobayashi, I; Matsuura, K; Nakamura, K; Nishikawa, G; Saito, H; Sumitomo, M; Tsukiyama, I; Yamada, Y; Yoshizawa, T; Zennami, K | 1 |
| Cohen, DJ; Cooper, CJ; Cutlip, DE; D'Agostino, RB; Dworkin, LD; Henrich, W; Jaff, MR; Jamerson, K; Lewis, EF; Massaro, JM; Matsumoto, AH; Murphy, TP; Prince, MR; Reid, DM; Rundback, JH; Shapiro, JI; Steffes, M; Tuttle, KR | 1 |
| Arlot-Bonnemains, Y; Belaud-Rotureau, MA; Dolley-Hitze, T; Goujon, JM; Jouan, F; Laguerre, B; Lorcy, N; Rioux-Leclercq, N; Verhoest, G; Vigneau, C | 1 |
| Jaimes, EA; Raij, L; Tian, R; Zhou, MS | 1 |
| Chattopadhyay, S; Dey, S; Mazumder, B | 1 |
| Cong, H; Fu, N; Jin, D; Li, H; Li, X; Ma, H; Wang, Y | 1 |
| Cho, EJ; Kim, JH; Sutradhar, S; Westergaard, M; Yunis, C | 1 |
| Akahori, H; Eguchi, A; Hirotani, S; Iwasaku, T; Masuyama, T; Matsumoto, M; Naito, Y; Sasaki, N; Sawada, H; Tsujino, T | 1 |
| Azushima, K; Dejima, T; Kanaoka, T; Kobayashi, R; Maeda, A; Ohsawa, M; Tamura, K; Toya, Y; Umemura, S; Uneda, K; Wakui, H | 1 |
| Breazna, A; Demetri, GD; Ewer, MS; Lenihan, DJ; Motzer, RJ; Niculescu, L; Suter, TM | 1 |
| Chen, W; Gao, DC; Ye, PX; Ye, PZ; Zhu, JH | 1 |
| de Ceuninck, M; Trenson, S | 1 |
| Kartashova, EA; Romantsov, MG; Sarvilina, IV | 1 |
| O'Brien, E | 1 |
| Baelde, HJ; Danser, AH; Kappers, MH; Lankhorst, S; Mathijssen, RH; Sleijfer, S; Smedts, FM; van den Meiracker, AH; van Esch, JH | 1 |
| Choudhury, S; Gupta, P; Harikumar, SK; Kannan, K; Mishra, SK; Pillai, AH; Sarath, TS; Sarkar, SN; Waghe, P | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Bono, P; Donskov, F; Joensuu, H; Peltola, K; Rautiola, J | 1 |
| Cserháti, A; Kahán, Z; Maráz, A; Szilágyi, E; Uhercsák, G; Varga, Z | 1 |
| Braun, D; Donner, A; Evert, K; Evert, M; Glöckl, G; Grisk, O; Katsari, E; Koenen, A; Löhn, M; Meissner, T; Plettenburg, O; Rettig, R; Steinbach, A; Zimmermann, U | 1 |
| Bespalova, ID; Kaliuzhin, VV; Mediantsev, IuA; Murashev, BIu; Osikhov, IA; Riazantseva, NV | 2 |
| Basso, U; Bonetti, A; Bracarda, S; Calabrò, F; Capaccetti, B; Cartenì, G; Ciuffreda, L; Fea, E; Ferrari, V; Fly, K; Gasparini, G; Gasparro, D; Hariharan, S; Labianca, R; Lo Re, G; Masini, C; Porta, C; Ruggeri, EM; Sternberg, CN; Tassinari, D; Zhang, K | 1 |
| Albiges, L; Derosa, L; Escudier, B; Izzedine, H; Le Teuff, G | 1 |
| Bochar, OM | 1 |
| Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D | 1 |
| Aoki, K; Arai, K; Homma, T; Ishikawa, H; Mizuno, M; Morikawa, Y; Sada, T; Tsuruoka, H; Ubukata, N | 1 |
| Pertijs, J; Rongen, GA; Thijs, AM; van den Broek, PH; van der Graaf, WT; van Herpen, CM; Verweij, V | 1 |
| Charles, LP; DeAnnuntis, L; Escudier, B; Gore, ME; Hariharan, S; Motzer, RJ; Porta, C; Rini, BI; Yang, L | 1 |
| Bilen, MA; Chen, HC; Hodges, S; Huang, S; Ilias-Khan, NA; Jonasch, E; Kearney, AY; Khakoo, AY; Tannir, NM; Wang, X; Zurita, AJ | 1 |
| Antón Aparicio, L; León-Mateos, L; Mosquera, J | 1 |
| Bjarnason, GA; Cohen, DP; Davis, MP; Donskov, F; Goldstein, D; Lin, X; Michaelson, MD; Motzer, RJ; Puzanov, I; Rini, BI; Wiltshire, R | 1 |
| Arai, K; Homma, T; Tsuruoka, H | 1 |
| Kichenadasse, G; Mangoni, AA; Rowland, A; Sorich, MJ; Woodman, RJ | 1 |
| Carpenter, C; Figlin, RA; Goldstein, D; McCann, L; Pandite, L; Rosenberg, JE; Townsend, RR | 1 |
| Belaustegui, A; Boven, E; Castellano, D; Diekstra, MH; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Anai, S; Fujimoto, K; Hayashi, Y; Hori, S; Hosokawa, Y; Kuwada, M; Miyake, M; Morizawa, Y; Nakagawa, Y; Nakai, Y; Otani, T; Otsuka, K; Samma, S; Tanaka, N; Tatsumi, Y; Tomioka, A | 1 |
| Ferenci, T; Simonyi, G | 1 |
| Blanchet, B; Da Silva, F; Goldwasser, F; Huillard, O; Thomas-Schoemann, A | 1 |
| Markovic, LE; Stein, TJ; Stepien, RL; Tjostheim, SS | 1 |
| Arai, K; Homma, T; Morikawa, Y; Tsuruoka, H; Ubukata, N | 1 |
| Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kwok, K; Riese, R; Soma, K; Wicker, P; Zuckerman, A | 1 |
| Wang, M; Zeng, R; Zhang, L | 1 |
| Cho, SN; Choi, SY; Jeong, MH; Jin, L; Kee, HJ; Kim, GR; Kim, HS; Lin, MQ; Ryu, Y; Yu, SY | 1 |
| Chi, Y; Cui, CX; Du, CX; Song, Y; Sun, Y; Sun, YK; Wang, JW; Yang, L; Zhang, W; Zhou, AP | 1 |
| Beutel, G; Drewes, N; Ganser, A; Grünwald, V; Ivanyi, P; Kielstein, JT; Morgan, M; Pirr, J | 1 |
| Bono, P; Peltola, K; Penttilä, P; Poussa, T; Rautiola, J | 1 |
| Baggstrom, MQ; Baker, S; Crawford, JA; Edelman, MJ; Feliciano, J; Gu, L; Hahn, O; Novotny, P; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, XF | 1 |
| Antón-Aparicio, LM; Leon, LA | 1 |
| Aubert, RE; Clore, G; Epstein, RS; Herrera, V; Kourlas, H; La-Beck, NM; McLeod, HL; Walko, CM | 1 |
| Guo, J; Hu, Z; Wang, Q; Wu, J; Wu, X; Xu, J; Yin, Z | 1 |
| Deedwania, P; Singh, V | 1 |
| Amarenco, P; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, M; Lamonte, M; Messig, M; Sillesen, H; Welch, KM | 1 |
| Humphreys, BD; Obhrai, JS; Patel, TV | 1 |
| Stergiopoulos, K; Wu, S; Zhu, X | 1 |
| Mehlsen, J | 1 |
| Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF | 1 |
| Kékes, E | 1 |
| Jain, R; Mathew, P; Tannir, NM; Wood, CG | 1 |
| Foody, JM; Honda, D; Leslie, RS; Nichol, MB; Patel, BV; Solomon, H; Tang, SS; Thiebaud, P | 1 |
| Chen, GP; Hu, SJ; Lu, X; Mou, Y; Yao, L; Zheng, LR | 1 |
| Chen, X; Liu, C; Peng, W; Qi, B; Wan, J; Yang, Q | 1 |
| Daher, IN; Yeh, ET | 1 |
| Coimbra, SR; Crisostomo, LM; Favarato, D; Luz, PL; Mendes, CM; Souza, CA | 1 |
| Zuber, M | 1 |
| Blanco-Colio, LM; Egido, J; Madrigal-Matute, J; Martín-Conejero, A; Martín-Ventura, JL; Muñoz-Garcia, B; Ortega, L; Serrano, J; Vega, M | 1 |
| Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ | 1 |
| Fujii, T; Kunita, E; Maeda, K; Sekiguchi, Y; Tasaki, N; Tsujiyama, S; Urabe, Y | 1 |
| Collier, D; Cruickshank, JK; Hughes, AD; Lacy, PS; Stanton, A; Thom, S; Thurston, H; Williams, B | 1 |
| Hanhart, J; Koskas, P; Le Mer, Y; Obadia, M; Paques, M; Sahel, JA | 1 |
| Bestermann, WH; Dyess, EM; Graff, A; Kursun, A; Neutel, JM; Sutradhar, S; Yunis, C | 1 |
| Beniak, J; Kakalejcik, M; Reckova, M | 1 |
| Izzedine, H; Massard, C; Soria, JC | 1 |
| Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Chen, Y; Cheng, X; Ding, Y; Liao, M; Liao, YH; Tang, T; Wang, M; Xia, C; Xie, J; Yao, R; Yu, X | 1 |
| Dahlof, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 2 |
| Maitland, ML; Snider, KL | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Agarwal, N; Chen, A | 1 |
| Ravaud, A; Sire, M | 1 |
| Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD | 1 |
| Bailey, AP; Gu, JW; Manning, RD; Sartin, B; Shparago, M; Young, E | 1 |
| Billemont, B; Kelly, RJ; Rixe, O | 1 |
| Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Nunzio, C; De Placido, S; Di Lorenzo, G; Ewer, M; Ficorella, C; Giordano, A; Giuliano, M; Gonnella, A; Montesarchio, V; Ricevuto, E; Rizzo, M; Romano, C; Tudini, M | 1 |
| Bangalore, S; Devabhaktuni, M | 1 |
| Goda, F; Himoto, T; Hosomi, N; Inukai, M; Kohno, M; Kohno, T; Masugata, H; Murao, K; Okuyama, H; Senda, S; Yamagami, A; Yukiiri, K | 1 |
| Benounna, M; Rivera, F; Sánchez de la Nieta, MD | 1 |
| Bamias, A; Dimopoulos, MA; Gyftaki, R; Koroboki, E; Lainakis, G; Manios, E; Zakopoulos, N | 1 |
| Brocheriou, I; Capron, F; Dupuis, M; Haloui, M; Louedec, L; Michel, JB; Nadaud, S; Soubrier, F | 1 |
| Abramczyk, P; Bidiuk, J; Ciarka, A; Dobosiewicz, A; Gaciong, Z; Lewandowski, J; Siński, M | 1 |
| Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK | 1 |
| Geng, J; Kang, W; Wang, W; Zhang, Y; Zhao, Z; Zhiming, GE | 1 |
| Hughes, AD; Manisty, C; Mayet, J; McG Thom, SA; Poulter, N; Sever, PS; Tapp, RJ | 1 |
| Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB | 1 |
| He, CC; He, WK; Liang, LY; Luo, BH; Su, CJ; Zeng, ZH; Zhang, ZH | 1 |
| Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K | 1 |
| Raczak, G | 1 |
| Edeline, J; Laguerre, B; Patard, JJ; Rolland, Y | 1 |
| Cui, W; Ibi, M; Ikami, K; Iwata, K; Kakehi, T; Katsuyama, M; Matsuno, K; Sasaki, M; Yabe-Nishimura, C; Zhu, K | 1 |
| Escudier, B; Gore, M; Mickisch, G; Nuijten, M; Procopio, G; Walzer, S | 1 |
| Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K | 2 |
| Boven, E; de Boer, MP; Eringa, EC; Serné, EH; Smulders, YM; van den Eertwegh, AJ; van der Veldt, AA; van Hinsbergh, VW | 1 |
| Kaminski, K; Knapp, M; Kozieradzka, A; Kuklinska, AM; Mroczko, B; Musial, WJ; Sawicki, R; Szmitkowski, M; Usowicz-Szarynska, M | 1 |
| Curran, MP | 1 |
| Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Tasci, I | 1 |
| Benner, JS; Chapman, RH; Foody, JM; Hussein, MA; Joyce, A; Solomon, HA; Tang, SS | 1 |
| Eckel, RH | 1 |
| Ghali, JK; Tam, SW | 1 |
| Grünwald, V; Kalanovic, D; Merseburger, AS | 1 |
| Perlamutrov, IuN; Shkol'nik, EL; Shkol'nik, MN; Vasiuk, IuA | 1 |
| Foody, JM; Liu, LZ; Mendys, PM; Simpson, RJ | 1 |
| Grimm, R; Kursun, A; Malik, M; Sutradhar, S; Yunis, C | 1 |
| Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C | 1 |
| Buxton, M; Dahlöf, B; Eriksson, J; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Derosa, G; Maffioli, P | 1 |
| Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C | 1 |
| Boven, E; de Boer, MP; Lankheet, NA; Serné, EH; van den Eertwegh, AJM; van der Veldt, AAM; Wijnstok, NJ | 1 |
| Funder, JW | 1 |
| Lopatin, IuM | 1 |
| Ginsberg, MS; Molina, AM; Motzer, RJ | 1 |
| Dhaun, N; Webb, DJ | 1 |
| Danser, AH; Kappers, MH; Sleijfer, S; Sluiter, W; van den Meiracker, AH; van Esch, JH | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA | 1 |
| Bangalore, S; DeMicco, D; Kostis, JB; LaRosa, JC; Messerli, FH; Wun, CC; Zuckerman, AL | 1 |
| Afonso-Afonso, FJ; Antón-Aparicio, LM; Aparicio-Gallego, G; Campos-Balea, B; Fernández-Calvo, O; Fírvida-Pérez, JL; Lázaro-Quintela, M; León-Mateos, L; Ramos-Vázquez, M; Vázquez-Estévez, S | 1 |
| Gomes, ME; Lenders, JW; Smits, P; Tack, CJ; Verheugt, FW | 1 |
| Bangalore, S; Cannon, CP; Murphy, SA; Qin, J; Sloan, S | 1 |
| Hirooka, Y; Kishi, T | 1 |
| Hu, SJ; Kang, L | 2 |
| Bono, P; Joensuu, H; Rautiola, J; Utriainen, T | 1 |
| Buch, J; Caulfield, MJ; Collier, DJ; Dahlöf, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Al-Khadra, A; Erdine, S; Kim, JH; Pavia, A; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Campo, N; Campo-Bustillo, I; Forteza, A; Gutierrez, J; Haussen, DC; Koch, S; Romano, JG | 1 |
| Baum, MS; Chen, I; Cohen, DP; Figlin, RA; Gore, ME; Hariharan, S; Lu, DR; Motzer, RJ; Rini, BI | 1 |
| Bamias, A; Constantinidis, C; Deliveliotis, C; Dimopoulos, MA; Karadimou, A; Lainakis, G; Manios, E; Michas, F; Zakopoulos, N | 1 |
| Ferreira-Sae, MC; Franchini, KG; Geloneze, B; Grespan-Magossi, AM; Nadruz, W; Pio-Magalhães, JA; Schreiber, R; Souza, FA; Velloso, LA | 1 |
| Al-Ahmadie, H; Bajorin, DF; Flaherty, AM; Gallagher, DJ; Garcia-Grossman, I; Gerst, SR; Gounder, SK; Milowsky, MI; Ostrovnaya, I; Regazzi, A; Riches, J; Trout, A | 1 |
| Horn, T; Jan Danser, AH; Kappers, MH; Leijten, F; Sleijfer, S; Smedts, FM; Strevens, H; van den Meiracker, AH; van Esch, JH; Wesseling, S | 1 |
| Caulfield, M; Chang, CL; Chapman, N; Dahlöf, B; Feder, G; Poulter, NR; Sever, PS | 1 |
| Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S | 1 |
| Filipiak, KJ; Langiewicz, P; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Zaborowska, M; Złnierek, J | 1 |
| Danser, AH; Kappers, MH; Sleijfer, S; van den Meiracker, AH | 1 |
| De Backer, GG | 1 |
| Chang, CL; Gupta, AK; Poulter, NR; Sever, PS; Whitehouse, A | 1 |
| Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Stafylas, PC; Tziolas, IM | 1 |
| Dreicer, R; Elson, P; Ganapathi, MK; Ganapathi, R; Garcia, JA; Kim, JJ; Rini, BI; Vaziri, SA; Wirka, R | 1 |
| Gupta, R; Maitland, ML | 1 |
| Anderson, L; Bhattacharya, S; Bose, N; Fraser, E; Graham, K; Lumsden, G; McClue, L; Robertson, L; Tho, LM; Yosef, H | 1 |
| Cheung, BM; Lam, KS; Li, M; Tse, HF; Xu, A | 1 |
| Antón-Aparicio, L; Aparicio-Gallego, G; Blanco, M; Figueroa, A; García-Campelo, R; Grande-Pulido, E; Valladares-Ayerbes, M | 1 |
| Betteridge, DJ; Calle, RA; Caulfield, M; Charlton-Menys, V; Chatterjee, A; Colhoun, HM; DeMicco, DA; Deshmukh, HA; Durrington, PN; Ford, I; Fuller, JH; Hitman, GA; Hyde, C; Johnson, T; Jukema, JW; Livingstone, S; McKeigue, PM; Neil, A; Postmus, I; Poulter, N; Sever, P; Shields, DC; Stanton, AV; Trompet, S | 1 |
| Guo, Y; Wang, J; Xu, D; Xu, J; Yang, Z; Zhang, Y; Zhou, C | 1 |
| Arsenault, BJ; Boekholdt, SM; Breazna, A; Deedwania, P; Demicco, DA; Kastelein, JJ; Mora, S; Waters, DD; Wenger, NK | 1 |
| Kishi, T; Sunagawa, K | 1 |
| Baigorria, ST; Eynard, AR; Fiore, MC; García, NH; Juncos, LA; Juncos, LI; Martín, FL; Pasqualini, ME | 1 |
| Budhiraja, RD; Sharma, S; Tyagi, S | 1 |
| Lazareva, NV; Oshchepkova, EV | 1 |
| de Jesus-Gonzalez, N; Humphreys, BD; Moslehi, J; Robinson, E | 1 |
| Cohen, DP; Demetri, GD; George, S; Lechner, T; Li, S; Reichardt, P | 1 |
| Al-Khadra, A; Erdine, S; Kim, JH; Pavia, A; Sutradhar, S; Yunis, C; Zamorano, J | 1 |
| Boven, E; Eechoute, K; Gelderblom, H; Guchelaar, HJ; Haanen, JB; Kappers, MH; Mathijssen, RH; Oosting, S; Reyners, AK; van der Veldt, AA; van Herpen, CM; Wessels, JA | 1 |
| Medvedev, IN; Skoriatina, IA | 1 |
| Amin, A; Badr El-Din, NK; Choi, SK; Kadowitz, P; Kevil, CG; Matrougui, K; Navar, LG; Osman-Elazeik, Y; Trebak, M | 1 |
| Delgado-Montero, A; Zamorano, JL | 1 |
| Huang, J; Huang, Y; Wang, T | 1 |
| Fedacko, J; Janicko, M; Jarcuska, P; Jedlickova, L; Kmec, J; Lopuchovsky, T; Merkovska, L; Pella, D; Sabol, F; Sajty, M | 1 |
| Raison, J; Rudnichi, A; Safar, ME | 1 |
| Beevers, DG; Lim, HS; Lip, GY; Nadar, S | 1 |
| Hirooka, Y; Kishi, T; Mukai, Y; Shimokawa, H; Takeshita, A | 1 |
| Lindholm, LH; Samuelsson, O | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 3 |
| Liebson, PR | 1 |
| SoRelle, R | 1 |
| Devroey, D; Ginst, LV | 1 |
| Killestein, J | 1 |
| Drummond, GA | 1 |
| Hackam, DG | 1 |
| Hedner, T; Himmelman, A; Kjeldsen, SE | 1 |
| Beniashvili, M; Freiman, A; Gavish, D; Leibovitz, E; Shargorodsky, M; Zimlichman, R | 1 |
| Banes, AK; Watts, SW | 2 |
| FREIS, ED; LILIENFIELD, LS; PARTENOPE, EA; ROSE, JC | 1 |
| Brown, WV; Moussa, M | 1 |
| Scheen, AJ | 1 |
| Kjeldsen, S; Midtbø, K; Svilaas, A; Syvertsen, JO; Westheim, A | 1 |
| Davalos, A; Fisher, M | 1 |
| Blanco-Colio, LM; Egido, J; Osende, JI; Ruiz-Ortega, M | 1 |
| Jukema, JW; van der Hoorn, JW | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
| McKerracher, A | 1 |
| Düsing, R; Klose, G; Szucs, TD | 1 |
| Jaimes, EA; Raij, L; Zhou, MS | 1 |
| Laustsen, G; Wimett, L | 1 |
| Madsen, S | 1 |
| Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A | 1 |
| Abdalla, DS; Aldrighi, JM; Bertolami, MC; Faludi, AA; Nakamura, Y; Pereira, IR; Ramires, JA; Saleh, MH; Silva, RA; Sousa, JE | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Berezovsky, A; Laszt, A; London, D; Magen, E; Mishal, J; Priluk, R; Viskoper, R; Yosefy, C | 1 |
| Brock, CM; Pitcock, J | 1 |
| Barraclough, D; Colman, PG; Reed, MD | 1 |
| Fushimi, H | 1 |
| Cárcamo, CA; Celedón, C; Nygren, CE; Paulós, CP | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Ahishali, B; Arican, N; Bilgic, B; Elmas, I; Kalayci, R; Kaya, M; Kucuk, M; Kudat, H; Uzun, H | 1 |
| Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L | 1 |
| Akcay, A; Bilgi, M; Bozbas, H; Kanbay, M; Muderrisoglu, H; Ozdemir, FN; Ulus, T; Yildirir, A | 1 |
| Cowie, MR | 1 |
| Gao, YJ; Lee, RM; Yang, L | 1 |
| Field, KM | 1 |
| Hobbs, FD | 1 |
| Armand, JP; Bello, C; Brega, N; Delbaldo, C; Deprimo, S; Faivre, S; Lassau, N; Lozahic, S; Massimini, G; Raymond, E; Robert, C; Scigalla, P; Vera, K | 1 |
| Bauer, B; Böhler, S; da Silva, PM; Feldman, R; Genest, J; Gensini, G; Harvey, P; Hobbs, FD; Jenssen, TG; Mancini, GB; Manolis, AJ; Metcalfe, M | 1 |
| Clearfield, M | 1 |
| Lynch, T | 1 |
| Huang, TG; Mondo, CK; Su, JZ; Yang, WS | 2 |
| Blank, R | 1 |
| Plummer, CJ | 1 |
| Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W | 1 |
| Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A | 1 |
| Demova, H; Kluckova, H; Komers, R; Lecian, D; Lodererova, A; Teplan, V; Voska, L; Zdychova, J | 1 |
| Carod-Artal, FJ | 1 |
| Huang, TG; Mondo, CK; Yang, WS; Zhang, N | 1 |
| Shah, DI; Singh, M | 2 |
| Blanco-Colio, LM; Duran, MC; Egido, J; Martín-Ventura, JL; Tuñon, J; Vivanco, F | 1 |
| Agustín Herrero, J; Cámara Hijón, C; Costo Campoamor, A; Crespo Rincón, L; Fernández Pereira, L; Pereira Navarro, G; Sánchez Muñoz-Torrero, JF; Torres Pérez, F | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Blank, R; Girerd, X; Hobbs, FD; Zamorano, J | 1 |
| Zhou, MS | 1 |
| Billemont, B; Izzedine, H; Rixe, O | 1 |
| McClendon, KS; Riche, DM | 1 |
| Katayama, Y; Katsumata, T; Nishiyama, Y; Otori, T; Tanaka, N | 1 |
| Hu, SJ; Sun, J; Zhang, ZJ | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L | 1 |
| Bayés, B; Blanco, S; Bonet, J; Lauzurica, R; Navarro-Muñoz, M; Romero, R | 1 |
| Brand, A; Gelderblom, H; Kapiteijn, E; Kroep, J | 1 |
| Arca, M | 1 |
| Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E | 1 |
| Hu, ZJ; Liu, DL; Wang, MP; Wu, G; Wu, J; Xu, GY | 1 |
| Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Sillesen, H; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Azizi, M; Chedid, A; Oudard, S | 1 |
| Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Bonomi, L; Imarisio, I; Paglino, C; Porta, C | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Adamidou, A; Giannopoulos, S; Hatzitolios, AI; Kosmidou, MS; Milionis, HJ; Parharidis, G; Raikos, N | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| Demetri, GD; George, S; Humphreys, BD; Maki, RG; Morgan, JA; Patel, TV; Quigley, M | 1 |
| Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y | 1 |
| McKeage, K; Siddiqui, MA | 1 |
| Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF | 1 |
| Pretnar-Oblak, J; Sabovic, M; Sebestjen, M | 1 |
| Breazna, A; Deedwania, PC; Kostis, JB; LaRosa, JC | 1 |
| Cachofeiro, V; Lahera, V | 1 |
| Imazu, C; Ishii, K; Kadokawa, T; Nakamura, H; Shimizu, M; Yokoyama, Y | 1 |
| Baldoli, E; Bellasio, E; Campi, A; Di Mola, N | 1 |
| Hashimoto, T; Kusano, S; Suzuki, S; Yano, K | 1 |
| Kam, KL; Pfaffendorf, M; van Zwieten, PA | 2 |
| Do, ML; Halterman, TJ; Howe, BB; Kau, ST; Li, JH; McConville, MW; Trivedi, S; Yochim, CL; Zografos, P | 1 |
| Clapham, JC; Hamilton, TC; Trail, BK | 1 |
| Addo, MF; Falotico, R; Giardino, E; Haertlein, BJ; Katz, LB; Loughney, D; McNally, JJ; Press, JB; Sanfilippo, PJ | 1 |
| Lee, BH; Oh, JH; Seo, HW; Shin, HS | 1 |
| Cooper, A; Kratzer, S; Pershad, A | 1 |
| Baird, TJ; Briscoe, RJ; Cabrera, CL; Rice, KC; Woods, JH | 1 |
| Ahlbory, K; Bäumer, AT; Böhm, M; Itter, G; Laufs, U; Linz, W; Müller, K; Nickenig, G; Rösen, R; Wassmann, S | 1 |
| Ichihara, K; Kaneta, S; Marumo, H; Satoh, K; Yamamoto, A | 1 |
| Ahlbory, K; Bäumer, AT; Böhm, M; Konkol, C; Laufs, U; Linz, W; Müller, K; Nickenig, G; Wassmann, S | 1 |
| Baguet, JP; Cameron, JD; Dart, AM; Ferrier, KE; Jennings, GL; Kingwell, BA; Muhlmann, MH | 1 |
| Banga, JD; Bots, ML; Huisman, MV; Stolk, RP; van de Ree, MA; van Venrooij, FV | 1 |
| Messing, MW; Struijker Boudier, HA; van Essen, H | 1 |
| Armstrong, JM; Barras, M; Hicks, PE; Lawson, K; Martin, DJ; Zazzi-Sudriez, E | 1 |
| Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL | 1 |
| Hosie, J; Meredith, P | 1 |
| Cachofeiro, V; Nasjletti, A; Sakakibara, T | 1 |
| Berdeaux, A; Giudicelli, JF; Richer, C | 1 |
| Grose, JH; Lacourcière, Y; Lebel, M | 2 |
| Haeusler, G | 1 |
| Miyata, N; Otomo, S; Tsuchida, K | 1 |
| Barthelmebs, M; Coquard, C; Giesen-Crouse, EM; Grima, M; Imbs, JL; Welsch, C | 1 |
| Burrell, G; Cassidy, F; Evans, JM; Lightowler, D; Stemp, G | 1 |
| Abe, Y; Aki, Y; Fukui, K; Iwao, H; Shoji, T; Tamaki, T | 1 |
| Collier, JG; Webb, DJ | 1 |
| MacGregor, GA; Markandu, ND; Miller, MA; Singer, DR; Sugden, AL | 1 |
| Carey, OJ; Davies, BE; Fleming, JJ; Ward, JW | 1 |
| Cheung, WM; Falotico, R; Haertlein, B; Keiser, J; Tobia, A | 1 |
| Buckingham, RE | 1 |
| Kimura, BK; Phillips, MI | 1 |
| Bock, KD; Hocevar, V; Merguet, P; Rausch-Stroomann, JG; Schley, G; Schröder, E; Schümann, HJ | 1 |
| Beattie, AD; Beveridge, GW; Goldberg, A; Hope, E; Hunter, JA; Khan, SA; Smith, AW | 1 |
42 review(s) available for pyrroles and Hypertension
| Article | Year |
|---|---|
Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Pyrroles; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone; Sulfones | 2021 |
Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
Topics: Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antagonists; Pyrroles; Sulfones | 2021 |
A low-density lipoprotein-dependent effect of atorvastatin upon the systolic blood pressure reduction: meta-regression analyses of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome | 2013 |
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib | 2015 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Hypertension; Indoles; Kidney Diseases; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Vascular complications of selected cancer therapies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases | 2008 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Quality of Life; Treatment Outcome | 2009 |
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Patient Compliance; Pyrroles; Treatment Outcome | 2010 |
The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Blood Pressure; Blood Volume; Female; Heart Failure; Humans; Hypertension; Hyponatremia; Male; Prevalence; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; United States; Water-Electrolyte Balance | 2010 |
Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach.
Topics: Carcinoma, Renal Cell; Consensus; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Evidence-Based Medicine; Fatigue; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Mouth Diseases; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Skin Diseases; Sunitinib; Treatment Outcome | 2010 |
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pyrroles | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotestosterone; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists; Ouabain; Pyrroles; Quinolines; Rats; Spironolactone | 2010 |
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
Molecular basis of hypertension side effects induced by sunitinib.
Topics: Angiogenesis Inhibitors; Humans; Hypertension; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Heart Failure; Humans; Hypertension; Indoles; Myocytes, Cardiac; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Risk Factors; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2011 |
New insights into molecular mechanisms of sunitinib-associated side effects.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Models, Biological; Pigmentation Disorders; Pyrroles; Signal Transduction; Sunitinib | 2011 |
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Emerging therapies for cerebrovascular disorders.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Intracranial Aneurysm; Pyrroles; Randomized Controlled Trials as Topic; Risk; Simvastatin; Therapeutics; Tissue Plasminogen Activator; Treatment Outcome | 2004 |
Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.
Topics: Atorvastatin; Clinical Trials Data Monitoring Committees; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy.
Topics: Amlodipine; Animals; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Combined Modality Therapy; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Pyrroles | 2004 |
A closer look at Caduet. The new generation of combination treatment.
Topics: Amlodipine; Drug Combinations; Drug Costs; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Pyrroles; United States | 2005 |
[Treatment of cerebral infarction patients with IGT].
Topics: Antidepressive Agents; Antipyrine; Atorvastatin; Cerebral Infarction; Edaravone; Free Radical Scavengers; Glucose Intolerance; Heptanoic Acids; Humans; Hyperglycemia; Hypertension; Hypertriglyceridemia; Insulin Resistance; Pyrroles; Secondary Prevention; Thrombolytic Therapy | 2005 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles; Risk Factors; Treatment Outcome | 2005 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Models, Biological; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides | 2006 |
A single-pill combination of amlodipine besylate and atorvastatin calcium.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles; Tablets | 2006 |
What's in the CARDS?
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Smoking | 2006 |
Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
Topics: Amlodipine; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2006 |
A single-pill combination of amlodipine besylate and atorvastatin calcium (update).
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2007 |
Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2007 |
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke | 2007 |
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2008 |
K(+)-channel openers: new antihypertensive drugs?
Topics: Antihypertensive Agents; Benzopyrans; Cromakalim; Dihydropyridines; Guanidines; Hemodynamics; Humans; Hypertension; Molecular Structure; Pinacidil; Potassium Channels; Pyrroles | 1990 |
88 trial(s) available for pyrroles and Hypertension
| Article | Year |
|---|---|
Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
Topics: Aged; Blood Pressure; Circadian Rhythm; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Pyrroles; Sulfones; Treatment Outcome | 2021 |
Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study.
Topics: Administration, Oral; Adult; Biological Availability; Cross-Over Studies; Food-Drug Interactions; Healthy Volunteers; Humans; Hypertension; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mineralocorticoid Receptor Antagonists; Pyrroles; Sulfones | 2019 |
Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Pyrroles; Treatment Outcome; Vascular Stiffness | 2013 |
Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors | 2013 |
Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Treatment Outcome | 2013 |
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2014 |
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biotransformation; Carcinoma, Renal Cell; China; Cohort Studies; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hypertension; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Postprandial Period; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sarcoma; Young Adult | 2013 |
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides | 2013 |
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Prevalence; Pyrroles; Risk Factors; Treatment Outcome | 2014 |
Stenting and medical therapy for atherosclerotic renal-artery stenosis.
Topics: Aged; Amlodipine; Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensive Agents; Cardiovascular Diseases; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Renal Artery; Renal Artery Obstruction; Renal Insufficiency, Chronic; Stents; Treatment Failure | 2014 |
Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Latin America; Male; Middle Aged; Middle East; Preventive Health Services; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2014 |
[Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension].
Topics: Aged; Atorvastatin; C-Reactive Protein; Double-Blind Method; Endothelins; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles | 2014 |
[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Atorvastatin; Blood Pressure; Blood Proteins; Drug Combinations; Drug Therapy, Combination; Echocardiography; Female; Flavin Mononucleotide; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Hypertensive Encephalopathy; Inosine Diphosphate; Male; Neuroprotective Agents; Niacinamide; Pyrroles; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinates; Systole; Tetrazoles; Valine; Valsartan | 2014 |
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Compassionate Use Trials; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Dysgeusia; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Neutropenia; Pyrroles; Stomatitis; Sunitinib; Thrombocytopenia; Treatment Outcome | 2015 |
[Pleiotropic effects of atorvastatin and dynamics of quality of life characteristics in patients with hypertensive disease and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypertension; Metabolic Syndrome; Middle Aged; Pyrroles; Quality of Life; Treatment Outcome | 2013 |
Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis.
Topics: Acetamides; Adipokines; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Benzoates; Breath Tests; Cholesterol, LDL; Drug Therapy, Combination; Fatty Liver; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Obesity; Pyrroles; Telmisartan; Triglycerides | 2014 |
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Fatigue; Female; Humans; Hypertension; Indoles; Intention to Treat Analysis; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mucositis; Neoplasm Staging; Neutropenia; Platinum Compounds; Pyrroles; Quality of Life; Sunitinib; Survival Rate; Thrombocytopenia | 2017 |
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Topics: Apolipoprotein A-I; Atorvastatin; Blood Pressure; Cholesterol; Data Interpretation, Statistical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Male; Middle Aged; Pyrroles; Reproducibility of Results; Sex Characteristics; Sex Factors; Stroke; Treatment Outcome; Triglycerides | 2008 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Treatment Outcome | 2009 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Pyrroles; Regional Blood Flow; Severity of Illness Index; Vasodilation | 2008 |
Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Carotid Artery Diseases; Carotid Stenosis; Chemokine CCL2; Cholesterol, LDL; Drug Synergism; Female; Heptanoic Acids; Humans; Hypertension; Macrophages; Male; Middle Aged; NF-kappa B; Pyrroles; RNA, Messenger | 2008 |
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebos; Pyrroles | 2009 |
Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
Topics: Aorta; Atorvastatin; Blood Pressure; Brachial Artery; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Placebos; Pulsatile Flow; Pyrroles; Radial Artery; Treatment Outcome | 2009 |
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Life Style; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2009 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Risk Factors; Risk Reduction Behavior; Sodium Chloride Symporter Inhibitors | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Tablets; Treatment Outcome | 2009 |
Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles | 2009 |
Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Cross-Over Studies; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Severity of Illness Index; Single-Blind Method | 2011 |
Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
Topics: Aged; Amlodipine; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure Determination; Carotid Arteries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Pulsatile Flow; Pyrroles; Reproducibility of Results; Scandinavian and Nordic Countries; Severity of Illness Index; United Kingdom; Vasodilator Agents | 2009 |
Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients - An open, pilot study.
Topics: Adult; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Pilot Projects; Pyrroles; Triglycerides | 2010 |
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cluster Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Internationality; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Surveys and Questionnaires | 2010 |
[Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension].
Topics: Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Psoriasis; Pyrroles; Quality of Life; Severity of Illness Index; Skin; Treatment Outcome | 2010 |
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tablets; Time Factors; Treatment Outcome; United States; Young Adult | 2010 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Disease; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Young Adult | 2010 |
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Markov Chains; Medication Adherence; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Risk Factors | 2010 |
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Topics: Aged; Angiotensin II; Animals; Blood Pressure; Bradykinin; Carcinoma, Renal Cell; Cells, Cultured; Coronary Circulation; Endothelial Cells; Endothelin-1; Female; Gastrointestinal Stromal Tumors; Heart; Heart Rate; Humans; Hypertension; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Rats; Rats, Inbred WKY; Receptor Protein-Tyrosine Kinases; Renin; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Sympathoinhibition by atorvastatin in hypertensive patients.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Norepinephrine; Prospective Studies; Pyrroles; Sympathetic Nervous System; Time Factors | 2010 |
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Proportional Hazards Models; Pyrroles; Risk Factors; Thrombolytic Therapy; Treatment Outcome | 2010 |
Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.
Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Pyrroles | 2011 |
Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Preventive Health Services; Pyrroles; Risk Factors; Standard of Care | 2011 |
High-dose atorvastatin enhances impaired cerebral vasomotor reactivity.
Topics: Aged; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Flow Velocity; Blood Pressure; Brain Infarction; Cerebrovascular Circulation; Chi-Square Distribution; Cholesterol, LDL; Female; Florida; Hemodynamics; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Middle Cerebral Artery; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2012 |
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Topics: Aged; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Ireland; Male; Middle Aged; Pyrroles; Racial Groups; Treatment Outcome; United Kingdom | 2011 |
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome | 2012 |
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Blood Pressure; Cholesterol; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome | 2011 |
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Topics: Adult; Aged; Atorvastatin; Cause of Death; Coronary Disease; Double-Blind Method; Early Termination of Clinical Trials; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2011 |
Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2012 |
Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin.
Topics: Adiponectin; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Biomarkers; Blood Pressure; Brachial Artery; Cholesterol; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography | 2011 |
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cardiopulmonary Resuscitation; Cholesterol, LDL; Death, Sudden, Cardiac; Female; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk; Sex Factors; Stroke | 2012 |
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Child; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Proactive cardiovascular risk management versus usual care in patients with and without diabetes mellitus: CRUCIAL trial subanalysis.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Pyrroles; Risk Factors; Risk Management; Treatment Outcome | 2012 |
Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Slovakia; Treatment Outcome | 2013 |
Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study.
Topics: Adult; Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Double-Blind Method; Elasticity; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse; Pyrroles; Statistics, Nonparametric; Treatment Outcome | 2002 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2003 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
[Statin therapy for hypertensive patients].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles | 2004 |
Treating to hypertension targets.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Determination; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles | 2004 |
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Therapy, Combination; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Tissue Plasminogen Activator | 2004 |
Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects.
Topics: Aged; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Estrogens; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Norethindrone; Progesterone; Pyrroles; Vasodilation | 2004 |
Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Ascorbic Acid; Atorvastatin; Blood Pressure; Brachial Artery; Cross-Sectional Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles | 2004 |
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Placebos; Pyrroles; Stroke; Treatment Outcome | 2005 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Disease; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2004 |
Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia.
Topics: Aged; Atorvastatin; Chile; Community Pharmacy Services; Drug-Related Side Effects and Adverse Reactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Pyrroles; Quality of Life | 2005 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke | 2005 |
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
Topics: Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Outpatients; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Female; Humans; Hypertension; Indoles; Male; Middle Aged; Neoplasms; Pigmentation; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Skin; Sunitinib | 2006 |
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha | 2006 |
Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cohort Studies; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Proteinuria; Pyrroles; Transforming Growth Factor beta | 2007 |
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Collagen; Coronary Disease; Diabetes Complications; Drug Resistance; Epinephrine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyrroles; Smoking | 2009 |
[Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China].
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzazepines; Carotid Arteries; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media | 2007 |
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspartate Aminotransferases; Atorvastatin; Blood Pressure; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles; Treatment Outcome | 2007 |
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Comorbidity; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrroles; Risk Assessment; Secondary Prevention; Sex Factors | 2008 |
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2008 |
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke | 2008 |
Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biological Transport; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Erythrocytes; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Linear Models; Lithium; Male; Middle Aged; Pyrroles; Sodium; Triglycerides | 2008 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Uric Acid; Ventricular Remodeling | 2008 |
The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Systole; Time Factors; Treatment Outcome | 2008 |
Antihypertensive effect of levcromakalim in patients with essential hypertension. Study by 24-h ambulatory blood pressure monitoring.
Topics: Adult; Aged; Antihypertensive Agents; Benzopyrans; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cromakalim; Female; Humans; Hypertension; Male; Middle Aged; Pulse; Pyrroles | 1995 |
Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.
Topics: Aged; Alanine Transaminase; Arteries; Aspartate Aminotransferases; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles; Systole; Triglycerides; Victoria | 2002 |
Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged; Placebos; Pyrroles; Smoking; Vasodilation | 2002 |
Effect of short-term administration of cromakalim on renal hemodynamics and eicosanoid excretion in essential hypertension.
Topics: Adult; Antihypertensive Agents; Atrial Natriuretic Factor; Benzopyrans; Blood Pressure; Chlorides; Cromakalim; Dinoprost; Dinoprostone; Eicosanoids; Female; Glomerular Filtration Rate; Heart Rate; Hemodynamics; Humans; Hypertension; Kidney; Male; Middle Aged; Potassium; Prostaglandins; Pyrroles; Regional Blood Flow; Renin-Angiotensin System; Sodium; Thromboxane B2; Time Factors; Vascular Resistance | 1991 |
Potassium channel stimulation in normal subjects and in patients with essential hypertension: an acute study with cromakalim (BRL 34915).
Topics: Antihypertensive Agents; Benzopyrans; Blood Pressure; Cromakalim; Double-Blind Method; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Potassium Channels; Pyrroles; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Stimulation, Chemical; Time Factors | 1989 |
218 other study(ies) available for pyrroles and Hypertension
| Article | Year |
|---|---|
Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Humans; Hypertension; Phenotype; Pyrroles; Sulfones | 2022 |
Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
Topics: Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Patient Safety; Pyrroles; Retrospective Studies; Stroke Volume; Sulfones; Treatment Outcome | 2021 |
Efficacy of esaxerenone-a nonsteroidal mineralocorticoid receptor blocker-on nocturnal hypertension.
Topics: Humans; Hypertension; Pyrroles; Receptors, Mineralocorticoid; Sulfones | 2022 |
Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
Topics: Antihypertensive Agents; Biomarkers; Blood Pressure; Essential Hypertension; Humans; Hypertension; Pyrroles; Sodium; Sulfones | 2022 |
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
Topics: Albumins; Albuminuria; Blood Pressure; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Hypertension; Potassium; Prospective Studies; Pyrroles; Sulfones | 2022 |
Blockade of PAR-1 Signaling Attenuates Cardiac Hypertrophy and Fibrosis in Renin-Overexpressing Hypertensive Mice.
Topics: Animals; Collagen Type III; Cytokines; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Fibrosis; HEK293 Cells; Humans; Hypertension; Hypertrophy, Left Ventricular; Inflammation Mediators; Macrophages; Male; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; Pyrroles; Quinazolines; Receptor, PAR-1; Renin; Signal Transduction; Transforming Growth Factor beta1; Up-Regulation; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Topics: Administration, Oral; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Glucuronosyltransferase; Humans; Hypertension; Intestinal Mucosa; Japan; Liver; Male; Microsomes, Liver; Midazolam; Mineralocorticoid Receptor Antagonists; Models, Biological; Pyrroles; Risk Assessment; Sulfones | 2020 |
[Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
Topics: Aged; Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Hypertension; Japan; Middle Aged; Mineralocorticoid Receptor Antagonists; Pyrroles; Rats; Sulfones; Tablets; Treatment Outcome | 2020 |
Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure.
Topics: Heart Failure; Humans; Hypertension; Pyrroles; Sulfones; Treatment Outcome | 2021 |
Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.
Topics: Animals; Cardiotonic Agents; Electrocardiography; Fibrosis; Hypertension; Inflammation; Male; Mineralocorticoid Receptor Antagonists; Pyrroles; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Sulfones; Survival Analysis; Ventricular Remodeling | 2021 |
MLK3 mediates impact of PKG1α on cardiac function and controls blood pressure through separate mechanisms.
Topics: Animals; Aorta; Blood Pressure; Cyclic GMP-Dependent Protein Kinase Type I; Heart Failure; HEK293 Cells; Humans; Hypertension; Male; MAP Kinase Kinase Kinases; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase Kinase Kinase 11; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrroles; Sildenafil Citrate; Vascular Stiffness; Vasodilator Agents; Ventricular Dysfunction, Left | 2021 |
Salt Sensitivity of Angiogenesis Inhibition-Induced Blood Pressure Rise: Role of Interstitial Sodium Accumulation?
Topics: Animals; Blood Pressure; Hypertension; Indoles; Lymphangiogenesis; Male; Pyrroles; Rats; Rats, Inbred WKY; Skin; Sodium, Dietary; Sunitinib | 2017 |
Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Australia; Blood Pressure; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Medication Adherence; Middle Aged; Pyrroles | 2017 |
Design, Synthesis and Evaluation of Novel 2-Hydroxypyrrolobenzodiazepine-5,11-dione Analogues as Potent Angiotensin Converting Enzyme (ACE) Inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzodiazepines; Binding Sites; Blood Pressure; Drug Design; Hypertension; Molecular Docking Simulation; Molecular Structure; Protein Binding; Pyrroles; Rats, Inbred SHR; Structure-Activity Relationship | 2017 |
Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Kidney Function Tests; Losartan; Male; Mineralocorticoid Receptor Antagonists; Pyrroles; Rats; Rats, Inbred Dahl; Renin; Sodium Chloride, Dietary; Sulfones | 2019 |
Esaxerenone: First Global Approval.
Topics: Clinical Trials, Phase III as Topic; Diabetic Nephropathies; Drug Approval; Humans; Hypertension; Japan; Mineralocorticoid Receptor Antagonists; Molecular Structure; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Mineralocorticoid; Sulfones | 2019 |
EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2018 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Effects of atorvastatin on the hypertension-induced oxidative stress in the rat brain.
Topics: Animals; Atorvastatin; Blood Pressure; Brain; Cardiomegaly; Catalase; Glutathione; Heptanoic Acids; Hypertension; Male; Malondialdehyde; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase | 2013 |
Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
Topics: Amlodipine; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; Drug Synergism; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Pyrroles; Risk Factors | 2013 |
Acute vascular effects of atorvastatin in hypertensive men: a pilot study.
Topics: Angiotensin II; Atorvastatin; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pilot Projects; Pyrroles; Regional Blood Flow; Vasoconstriction; Vasodilation | 2013 |
The effects of atorvastatin on oxidative stress in L-NAME-treated rats.
Topics: Animals; Aryldialkylphosphatase; Atorvastatin; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Peroxidation; Lipids; Male; NG-Nitroarginine Methyl Ester; Oxidative Stress; Protein Carbonylation; Pyrroles; Rats; Rats, Wistar; Sulfhydryl Compounds | 2013 |
Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation.
Topics: Adult; Atorvastatin; Atrial Fibrillation; Atrial Function, Left; Echocardiography; Female; Heart Atria; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles | 2013 |
The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endotheli
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Coronary Vessels; Cyclooxygenase 2 Inhibitors; Endothelium; Endothelium-Dependent Relaxing Factors; Hypertension; Male; Nitrates; Nitric Oxide; Nitrites; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Regional Blood Flow | 2013 |
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes.
Topics: Aged; Blood Pressure Determination; Carcinoma, Renal Cell; Disease Management; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Compliance; Prognosis; Pyrroles; Sunitinib | 2013 |
All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Hypertension; Immunohistochemistry; Indoles; Kidney Failure, Chronic; Kidney Glomerulus; Kidney Neoplasms; Male; Middle Aged; Proteinuria; Pyrroles; Registries; Retrospective Studies; Sunitinib; Syndrome; Vascular Endothelial Growth Factor A | 2014 |
Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy; Male; Nitric Oxide Synthase Type III; Pyrroles; Rats, Inbred Dahl; Scavenger Receptors, Class E; Sodium Chloride, Dietary; Superoxides; Time Factors; Vasodilation | 2014 |
Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.
Topics: Administration, Oral; Atenolol; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Solubility | 2014 |
Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.
Topics: Acute Kidney Injury; Aged; Antioxidants; Atorvastatin; Biomarkers; Contrast Media; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Function Tests; Male; Middle Aged; Perioperative Period; Probucol; Prospective Studies; Pyrroles; Risk Factors; Uric Acid | 2014 |
Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Failure, Diastolic; Heptanoic Acids; HSP47 Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Myocardium; Pyrroles; Rats; Rats, Inbred Dahl; rho-Associated Kinases; Ventricular Function, Left | 2014 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug Therapy, Combination; Female; Glucose; Heptanoic Acids; Humans; Hypertension; Inflammation; Kidney; Kidney Function Tests; Lipid Metabolism; Male; Multivariate Analysis; Oxidative Stress; Pyrroles; Regression Analysis; Renal Insufficiency, Chronic | 2014 |
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Humans; Hypertension; Incidence; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Middle Aged; Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sunitinib | 2014 |
A calcified left ventricular mass.
Topics: Aged, 80 and over; Aging; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Calcinosis; Diagnosis, Differential; Female; Heart Neoplasms; Heart Valve Diseases; Heptanoic Acids; Humans; Hypertension; Mitral Valve; Monitoring, Physiologic; Platelet Aggregation Inhibitors; Pyrroles; Quinapril; Radiography; Tetrahydroisoquinolines; Treatment Outcome | 2014 |
If I had resistant hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Pyrroles; Spironolactone; Tetrazoles; Treatment Failure; Treatment Outcome | 2014 |
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Topics: Acute Kidney Injury; Amlodipine; Angiogenesis Inhibitors; Animals; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Follow-Up Studies; Glomerular Filtration Rate; Hypertension; Indoles; Pyrimidines; Pyrroles; Rats; Rats, Inbred WKY; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Atorvastatin ameliorates arsenic-induced hypertension and enhancement of vascular redox signaling in rats.
Topics: Animals; Aorta, Thoracic; Arsenites; Atorvastatin; Catalase; Cholesterol; Glutathione Peroxidase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Random Allocation; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sodium Compounds; Superoxide Dismutase; Tyrosine | 2014 |
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Topics: Aged; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Artery Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Ultrasonography, Interventional | 2014 |
Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Treatment Outcome | 2016 |
[Therapeutic significance of sunitinib-induced "off-target" side effects].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Stomatitis; Sunitinib; Treatment Outcome | 2014 |
Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
Topics: Aged; Animals; Antineoplastic Agents; Arterial Pressure; Blood Pressure; Female; Humans; Hypertension; Indoles; Kidney Tubules; Male; Middle Aged; Pyrroles; Rats; Receptors, Vascular Endothelial Growth Factor; rho-Associated Kinases; Sodium; Sodium, Dietary; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Resistance; Vasodilation | 2014 |
[Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Cytokines; Dose-Response Relationship, Drug; Drug Monitoring; Essential Hypertension; Female; Heptanoic Acids; Humans; Hypertension; Inflammation; Leukocytes, Mononuclear; Male; Metabolic Syndrome; Middle Aged; Patient Acuity; Prospective Studies; Pyrroles; Reactive Oxygen Species; Severity of Illness Index; Treatment Outcome | 2014 |
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; France; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Renin-Angiotensin System; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Topics: Administration, Oral; Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Binding, Competitive; Blood Pressure; Desoxycorticosterone Acetate; Disease Models, Animal; Dose-Response Relationship, Drug; Eplerenone; Female; HEK293 Cells; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Potassium; Protein Binding; Pyrroles; Rabbits; Radioligand Assay; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium; Spironolactone; Sulfones; Transcriptional Activation; Transfection; Urological Agents; Water-Electrolyte Balance | 2015 |
Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension.
Topics: Acetylcholine; Adult; Aged; Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Endothelium, Vascular; Forearm; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Mesenteric Arteries; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroprusside; Pyrroles; Rats; Regional Blood Flow; Sunitinib; Vascular Endothelial Growth Factor A; Vasodilation; Vasodilator Agents | 2015 |
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Topics: Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Dysgeusia; Dyspepsia; Fatigue; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Mucositis; Nausea; Pyrroles; Stomatitis; Sunitinib; Time Factors | 2016 |
Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Humans; Hypertension; Indoles; Nitric Oxide Donors; Pyrroles; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2015 |
CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cytoprotection; Heart; Hypertension; Kidney; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Organ Size; Potassium; Pyrroles; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Safety; Sulfones | 2015 |
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chi-Square Distribution; Cytochrome P-450 CYP3A; Disease-Free Survival; Europe; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hypertension; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Ohio; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2017 |
The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study.
Topics: Aged; Carcinoma, Renal Cell; Demography; Disease-Free Survival; Female; Humans; Hypertension; Incidence; Indoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Linear Models; Male; Medication Adherence; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2016 |
Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker.
Topics: Aged; Calcium Channel Blockers; Carcinoma, Renal Cell; Drug Interactions; Drug Monitoring; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2016 |
Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Case-Control Studies; Cohort Studies; Dog Diseases; Dogs; Hypertension; Indoles; Neoplasms; Prospective Studies; Protein-Tyrosine Kinases; Proteinuria; Pyrroles | 2016 |
CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
Topics: Animals; Blood Pressure; Desoxycorticosterone Acetate; Gene Expression Regulation; Hypertension; Kidney; Male; Mineralocorticoid Receptor Antagonists; Organ Size; Pyrroles; Rats; Receptors, Mineralocorticoid; RNA, Messenger; Sodium Chloride, Dietary; Sulfones | 2016 |
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Topics: Arthritis, Rheumatoid; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Hyperlipidemias; Hypertension; Incidence; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2016 |
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Case-Control Studies; Disease Management; Drug Administration Schedule; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles | 2016 |
Histone deacetylase and GATA-binding factor 6 regulate arterial remodeling in angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Cycle Proteins; Cell Nucleus; Cell Proliferation; Cells, Cultured; DNA; GATA6 Transcription Factor; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Hypertension; Hypertrophy; Kidney; Male; Mice; Muscle, Smooth, Vascular; Phosphorylation; Pyrroles; Repressor Proteins; Vascular Remodeling | 2016 |
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium Channel Blockers; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2017 |
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
Topics: Female; Humans; Hypertension; Indoles; Male; Neoplasms; Neovascularization, Pathologic; Nitric Oxide Donors; Pyrroles; Sunitinib | 2015 |
Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
Topics: Cohort Studies; Female; Humans; Hypertension; Hypothyroidism; Indoles; Male; Middle Aged; Niacinamide; Pharmacoepidemiology; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2017 |
Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Cattle; Cerebellum; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Injections, Intravenous; Liver; Losartan; Male; Protein Binding; Pyrroles; Rabbits; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Time Factors; Triazoles; Vasoconstriction | 2008 |
The case / progressive hypertension and proteinuria on anti-angiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Indoles; Kidney; Models, Biological; Proteinuria; Pyrroles; Sunitinib; Syndrome; Vascular Endothelial Growth Factor A | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumethiazide; Cardiovascular Diseases; Cost-Benefit Analysis; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Treatment Outcome | 2008 |
Sunitinib-induced acute hemolysis without hypertension: a case report.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Hemolysis; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2008 |
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen.
Topics: Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles; Retrospective Studies | 2008 |
Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blotting, Western; Calcium-Binding Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cytokines; Enzyme-Linked Immunosorbent Assay; Gene Expression; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Ventricular Function, Left | 2009 |
Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats.
Topics: Animals; Aortic Diseases; Atorvastatin; Blood Pressure; Calcinosis; Heptanoic Acids; Hypertension; Male; Pyrroles; Random Allocation; Rats; Rats, Wistar; Warfarin | 2008 |
[Vascular prevention after cerebral infarct or transient ischemic accident. Recommendations. March, 2008].
Topics: Anticholesteremic Agents; Atorvastatin; Brain; Cerebral Infarction; Cerebrovascular Circulation; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Time Factors | 2008 |
Coronary plaque stabilization followed by Color Code Plaque analysis with 64-slice multidetector row computed tomography.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Stenosis; Coronary Vasospasm; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Tomography, X-Ray Computed; Ultrasonography | 2009 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary Body; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Light Coagulation; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Ophthalmic Artery; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Stroke; Ultrasonography | 2008 |
Treatment of hemodialyzed patient with sunitinib.
Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Artery Bypass; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Indoles; Male; Middle Aged; Nausea; Nephrectomy; Pyrroles; Remission Induction; Renal Dialysis; Sunitinib; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |
From theoretical synergy to clinical supra-additive toxicity.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug Synergism; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Biomarkers; Case-Control Studies; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-18; Interleukin-4; Male; Middle Aged; Pyrroles; Th1 Cells; Th2 Cells | 2009 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome | 2009 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Models, Economic; Pyrroles; Scandinavian and Nordic Countries; Treatment Outcome | 2009 |
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Topics: Age Factors; Aged; Atorvastatin; Causality; Cerebral Hemorrhage; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Iatrogenic Disease; Intracranial Arteriosclerosis; Male; Pyrroles; Sex Factors | 2009 |
Reversible posterior leucoencephalopathy syndrome associated with sunitinib.
Topics: Female; Humans; Hypertension; Indoles; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrroles; Sunitinib | 2009 |
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats.
Topics: Albuminuria; Angiogenesis Inhibitors; Animals; Blood Pressure; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Epithelial Cells; Heart Rate; Humans; Hypertension; Indoles; Injections, Intraperitoneal; Kidney; Kidney Glomerulus; Kidney Tubules, Proximal; Male; Natriuresis; Nitric Oxide; Nitric Oxide Synthase Type III; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Vascular Endothelial Growth Factor; Sodium Chloride, Dietary; Vascular Endothelial Growth Factor A | 2009 |
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Disease; Female; Heart; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Stroke Volume; Sunitinib; Ventricular Function, Left | 2009 |
Early detection of hypertension in a patient treated with sunitinib by measuring cardio-ankle vascular index.
Topics: Aged, 80 and over; Ankle Brachial Index; Blood Flow Velocity; Blood Pressure; Diastole; Female; Humans; Hypertension; Indoles; Pyrroles; Stroke Volume; Sunitinib; Ultrasonography | 2009 |
Sunitinib-aggravated hypertension.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2009 |
Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.
Topics: Aged; Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Prospective Studies; Pyrroles; Sunitinib | 2009 |
Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection.
Topics: Animals; Aorta; Atorvastatin; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Hypertension; Male; NG-Nitroarginine Methyl Ester; Pyrroles; Rats; Rats, Inbred F344 | 2009 |
Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; MEF2 Transcription Factors; Myocardium; Protein Kinase C; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Time Factors; Transcription Factors; Ventricular Remodeling | 2010 |
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2010 |
The functional changes of the perivascular adipose tissue in spontaneously hypertensive rats and the effects of atorvastatin therapy.
Topics: Adipose Tissue; Animals; Aorta, Thoracic; Atorvastatin; Connective Tissue; Disease Models, Animal; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasoconstriction; Vasodilation | 2009 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2009 |
[Atorvastatin dreduces sympathetic activity and improves baroreceptor reflex sensitivity in patients with hypercholesterolemia and hypertension].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles | 2009 |
Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Topics: Antihypertensive Agents; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Pyrroles; Sirolimus; Sunitinib | 2010 |
NADPH oxidase isoforms and anti-hypertensive effects of atorvastatin demonstrated in two animal models.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Apolipoproteins E; Atorvastatin; Blood Pressure; Blotting, Western; Dietary Fats; Ethidium; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase; Pyrroles; rac1 GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; France; Gastrointestinal Diseases; Germany; Health Care Costs; Hematologic Diseases; Hospital Costs; Hospitalization; Humans; Hypertension; Indoles; Interferon alpha-2; Interferon-alpha; Italy; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Recombinant Proteins; Sunitinib; United Kingdom; Venous Thrombosis | 2010 |
Atorvastatin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP.
Topics: Animals; Atorvastatin; Baroreflex; Blood Pressure; Disease Models, Animal; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Medulla Oblongata; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2009 |
Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Baroreflex; Heptanoic Acids; Hypertension; Injections, Intraventricular; Male; Medulla Oblongata; NADP; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Superoxide Dismutase; Sympathetic Nervous System | 2010 |
Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Capillaries; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Skin; Sunitinib | 2010 |
Clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Diabetes Mellitus; Fatty Liver; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2010 |
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Managed Care Programs; Medication Adherence; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies | 2010 |
Approach to the patient who is intolerant of statin therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Coronary Disease; Diltiazem; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Pyrroles; Simvastatin | 2010 |
The utility of observational studies in clinical decision making: lessons learned from statin trials.
Topics: Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Decision Making; Epidemiologic Studies; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Observation; Pyrroles; Simvastatin | 2010 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Databases, Factual; Drug Therapy, Combination; Female; Health Records, Personal; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk; Risk Factors; Risk Reduction Behavior | 2010 |
Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon.
Topics: Angiogenesis Inhibitors; Capillaries; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Palliative Care; Pyrroles; Skin; Sunitinib | 2010 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Monitoring; Drug Synergism; Dyslipidemias; Heart Diseases; Heptanoic Acids; Humans; Hypertension; Patient Compliance; Pyrroles; Risk Factors | 2010 |
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Hypercholesterolemia; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Randomized Controlled Trials as Topic; Salvage Therapy; Sirolimus; Sunitinib | 2011 |
Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?
Topics: Blood Pressure; Carcinoma, Renal Cell; Endothelin-1; Gastrointestinal Stromal Tumors; Heart Rate; Humans; Hypertension; Indoles; Kidney Neoplasms; Models, Biological; Proteinuria; Pyrroles; Receptor Protein-Tyrosine Kinases; Renin; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity; Data Interpretation, Statistical; Dyslipidemias; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Hematocrit; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Time Factors | 2010 |
Sympathoinhibitory effects of atorvastatin in hypertension.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Norepinephrine; Prospective Studies; Pyrroles; Sympathetic Nervous System; Time Factors | 2010 |
[Effects of atorvastatin on p27 protein expression and cardiomyocytes apoptosis in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cyclin-Dependent Kinase Inhibitor p27; Heptanoic Acids; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; RNA, Messenger | 2008 |
Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Risk Factors; Sunitinib | 2011 |
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Confounding Factors, Epidemiologic; Disease-Free Survival; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Treatment Outcome | 2011 |
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Benzopyrans; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Ethanolamines; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Irbesartan; Male; Middle Aged; Nebivolol; Prevalence; Pyrroles; Reproducibility of Results; Sunitinib; Tetrazoles; Time Factors; Treatment Outcome | 2011 |
Hip circumference is associated with high density lipoprotein cholesterol response following statin therapy in hypertensive subjects.
Topics: Aged; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Waist Circumference; Waist-Hip Ratio | 2011 |
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Pressure; Carcinoma, Transitional Cell; Cell Cycle Proteins; Drug Administration Schedule; Humans; Hypertension; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Logistic Models; New York City; Phosphoproteins; Phosphorylation; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Tissue Array Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Urologic Neoplasms; Urothelium; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Dose-Response Relationship, Drug; Endothelin-1; Hypertension; Indoles; Kidney; Male; Nitric Oxide; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Humans; Hypertension; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Pyrroles | 2011 |
Long-term results from statin trials: answers but more unresolved questions.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles | 2011 |
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Trastuzumab-related palmar plantar erythrodysaesthesia.
Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agents; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Foot Dermatoses; Hand Dermatoses; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Trastuzumab | 2012 |
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Genome-Wide Association Study; Genotype; Glucosyltransferases; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebo Effect; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysophosphatidic Acid; Treatment Outcome | 2012 |
Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Anticholesteremic Agents; Arteries; Atorvastatin; Biomarkers; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Statistics as Topic; Statistics, Nonparametric | 2012 |
Combination therapy of atorvastatin and amlodipine inhibits sympathetic nervous system activation and improves cognitive function in hypertensive rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Antioxidants; Atorvastatin; Cognition; Drug Therapy, Combination; Heptanoic Acids; Hippocampus; Hypertension; Male; Nerve Tissue Proteins; Pyrroles; Rats; Rats, Inbred SHR; Superoxide Dismutase; Sympathetic Nervous System | 2012 |
Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
Topics: Animals; Atorvastatin; Blood Pressure; Creatinine; Diet; Fatty Acids, Unsaturated; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Male; Nephrectomy; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sodium; Sodium Chloride, Dietary | 2012 |
Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Atorvastatin; Blood Pressure; Desoxycorticosterone; Endothelium, Vascular; Female; Glutathione; Heptanoic Acids; Hypertension; Losartan; Male; Nitrates; Nitrites; Phosphoinositide-3 Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; Thiazolidinediones | 2012 |
[Painless myocardial ischemia in patient with extensive constrictive atherosclerosis of coronary arteries].
Topics: Angioplasty; Anticholesteremic Agents; Asymptomatic Diseases; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Echocardiography; Electrophysiologic Techniques, Cardiac; Exercise Test; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
Management of antiangiogenic therapy-induced hypertension.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Hypertension; Indoles; Kidney Neoplasms; Lisinopril; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome; Withholding Treatment | 2012 |
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
[Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Comorbidity; Dyslipidemias; Erythrocytes; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Rheology; Severity of Illness Index | 2012 |
Sodium nitrite therapy rescues ischemia-induced neovascularization and blood flow recovery in hypertension.
Topics: Allopurinol; Angiotensin II; Animals; Arterial Pressure; Capillaries; Cyclic AMP; Cyclic GMP; Femoral Artery; Hindlimb; Hypertension; Indoles; Ischemia; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Neovascularization, Pathologic; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow; Sodium Nitrite; Xanthine Dehydrogenase | 2012 |
Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Carcinoma, Renal Cell; Cyclooxygenase 2 Inhibitors; Esophagitis; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Tetrazoles; Valine; Valsartan | 2013 |
Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; Brain; Genetic Predisposition to Disease; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Lipids; Male; Myocardium; Neural Inhibition; Nitric Oxide Synthase; Norepinephrine; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Sympathetic Nervous System; Up-Regulation | 2003 |
What are the odds at ASCOT today?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
New lipid-lowering combo proves successful.
Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Sex Factors | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hypertension; Pyrroles; Research Design | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black People; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Risk Factors | 2003 |
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
Statins benefit people with high blood pressure.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2003 |
In light of ALLHAT and ASCOT: are there benefits of statins as add-on treatment in hypertensives?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Evaluation; Heptanoic Acids; Humans; Hypertension; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin; Stroke; Treatment Outcome | 2003 |
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteries; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Diastole; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Stroke Volume; Systole; Treatment Outcome; Vascular Resistance | 2003 |
[Statin soon to become standard addition to antihypertensive therapy? Better prevention of coronary heart disease for hypertensive patients].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension.
Topics: Animals; Arteries; Desoxycorticosterone; Female; Gene Expression; Hypertension; Indoles; Male; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2B; Serotonin Antagonists; Serotonin Receptor Agonists; Sodium Chloride; Thiophenes; Vasoconstriction | 2003 |
A clinical appraisal of pentapyrrolidinium (M&B 2050) in hypertensive patients.
Topics: Autonomic Agents; Cardiovascular Agents; Hypertension; Muscle Relaxants, Central; Pyrroles | 1954 |
[Following the ASCOT Study. A statin for every hypertensive patient?].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Treatment Outcome | 2003 |
[Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Diabetes Complications; Ethics, Research; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Ireland; Pyrroles; Risk Factors; Scandinavian and Nordic Countries; United Kingdom | 2003 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
[Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Female; Germany; Health Care Costs; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2004 |
Amlodipine/atorvastatin (Caduet).
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles | 2004 |
Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress.
Topics: Animals; Aorta; Atorvastatin; Down-Regulation; Endothelium, Vascular; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Organ Size; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Sodium, Dietary | 2004 |
Caduet treats two cardiovascular conditions at once.
Topics: Amlodipine; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Practice Guidelines as Topic; Pyrroles; Risk Assessment; Risk Factors | 2004 |
[Statins and hypertension].
Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Heptanoic Acids; Humans; Hypertension; Pyrroles; Stroke | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Cyclical Cushing's disease causing recurrent oedema and knee effusions.
Topics: Adult; Antihypertensive Agents; Atorvastatin; Diuretics; Drug Therapy, Combination; Edema; Enalapril; Follow-Up Studies; Heptanoic Acids; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Knee; Male; Pituitary ACTH Hypersecretion; Pyrroles; Sodium Chloride Symporter Inhibitors | 2005 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
Effects of atorvastatin on blood-brain barrier permeability during L-NAME hypertension followed by angiotensin-II in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Blood-Brain Barrier; Heptanoic Acids; Hypertension; Male; NG-Nitroarginine Methyl Ester; Permeability; Pyrroles; Rats; Rats, Wistar | 2005 |
The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Apoptosis; Arteries; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; In Situ Nick-End Labeling; In Vitro Techniques; Male; Mesenteric Arteries; Microscopy, Confocal; Nitroprusside; Norepinephrine; Pyrroles; Quinapril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrahydroisoquinolines; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Doxazosin; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Sodium Chloride Symporter Inhibitors; Treatment Outcome | 2005 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Multicenter Studies as Topic; Pyrroles; Surveys and Questionnaires; Tablets | 2006 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2006 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Prescriptions; Drugs, Generic; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Metoprolol; Patient Compliance; Pharmacists; Pyrroles; Self Administration | 2006 |
Atorvastatin prevented and partially reversed adrenocorticotropic hormone-induced hypertension in the rat.
Topics: Adrenocorticotropic Hormone; Animals; Atorvastatin; Blood Pressure; Body Weight; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides | 2006 |
Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
Topics: Analysis of Variance; Animals; Atorvastatin; Biomarkers; Blood Pressure; Body Weight; Dexamethasone; Disease Models, Animal; Down-Regulation; Glucocorticoids; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Thymus Gland | 2006 |
Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis.
Topics: Albuminuria; Analysis of Variance; Animals; Atorvastatin; Blood Pressure; Caveolin 1; Glomerular Filtration Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Models, Animal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Vascular Endothelial Growth Factor A | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.
Topics: Animals; Antioxidants; Aorta; Atorvastatin; Dexamethasone; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hypertension; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; Vasoconstriction; Vasodilation | 2006 |
Possible role of exogenous cAMP to improve vascular endothelial dysfunction in hypertensive rats.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Aorta; Atorvastatin; Blood Pressure; Cyclic AMP; Drug Administration Schedule; Endothelium, Vascular; Heptanoic Acids; Hypertension; Male; NADPH Oxidases; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Thiobarbituric Acid Reactive Substances; Vasodilation | 2006 |
[Effects of atorvastatin in N-terminal pro-brain natriuretic peptide plasma levels in hypercholesterolemic patients with or without hypertension].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyrroles | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
Effect of demethylasterriquinone b1 in hypertension associated vascular endothelial dysfunction.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Microscopy, Electron; Muscle Relaxation; Muscle, Smooth, Vascular; NADPH Oxidases; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Superoxides; Thiobarbituric Acid Reactive Substances | 2007 |
[Effect of atorvastatin on left ventricular remodeling in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Blood Pressure; Heptanoic Acids; Hydroxyproline; Hypertension; Lipids; Male; Myocardium; Proliferating Cell Nuclear Antigen; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Up-Regulation; Ventricular Remodeling | 2007 |
Upregulation of nitric oxide, inhibition of oxidative stress, and antihypertensive effects of statins.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Nitric Oxide; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Up-Regulation; Vasoconstriction | 2007 |
Hypertension as a predictive factor of Sunitinib activity.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2007 |
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arginine; Atorvastatin; Brain; Cerebral Arteries; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Metabolism; Male; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Time; Time Factors; Treatment Outcome | 2007 |
[Effects of atorvastatin on endothelium protection in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Endothelium, Vascular; Heptanoic Acids; Hypertension; Lipids; Male; Nitric Oxide; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; von Willebrand Factor | 2007 |
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
Topics: Antineoplastic Agents; Female; Humans; Hypertension; Indoles; Middle Aged; Neurotoxicity Syndromes; Purpura, Thrombotic Thrombocytopenic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Home blood-pressure monitoring in patients receiving sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Heart Rate; Home Nursing; Humans; Hypertension; Indoles; Kidney Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Telemedicine | 2008 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib | 2008 |
Systemic evaluation of gene expression changes in major target organs induced by atorvastatin.
Topics: Animals; Atorvastatin; Blood Pressure; Brain; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Lipids; Male; Myocardium; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reproducibility of Results; RNA, Messenger; Time Factors | 2008 |
Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension.
Topics: Arginine; Atorvastatin; Blood Circulation; Cerebrovascular Circulation; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Ultrasonography, Doppler, Transcranial | 2008 |
Specific amelioration of cerebral endothelial dysfunction in hypertensive patients treated with atorvastatin.
Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles | 2008 |
Site of analgesic action of zomepirac sodium, a potent non-narcotic analgesic in experimental animals.
Topics: Alprostadil; Analgesics; Animals; Ascitic Fluid; Bradykinin; Dogs; Hypertension; Injections, Intraventricular; Male; Naloxone; Pain; Prostaglandins E; Pyrroles; Rats; Rats, Inbred Strains; Tolmetin | 1983 |
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
Topics: Animals; Antihypertensive Agents; Dogs; Heart Rate; Hydralazine; Hypertension; Hypertension, Renal; Mutagenicity Tests; Pyridazines; Pyrroles; Rats | 1984 |
Drug-induced endothelium-dependent and -independent relaxations in isolated resistance vessels taken from simultaneously hypertensive and streptozotocin-diabetic rats.
Topics: Animals; Benzopyrans; Bradykinin; Calcium; Cromakalim; Diabetes Mellitus, Experimental; Endothelium, Vascular; Glyburide; Histamine; Hypertension; Male; Mesenteric Arteries; Methacholine Chloride; Muscle Relaxation; Muscle, Smooth, Vascular; Nifedipine; Nitroprusside; Potassium Channels; Potassium Chloride; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Streptozocin; Vascular Resistance; Vasodilation; Vasodilator Agents | 1994 |
Characterization of ATP-sensitive potassium channel-blocking activity of ZENECA ZM181,037, a eukalemic diuretic.
Topics: Acetamides; Adenosine Triphosphate; Administration, Oral; Animals; Benzopyrans; Blood Glucose; Blood Pressure; Cromakalim; Diuretics; Dogs; Dose-Response Relationship, Drug; Electrophysiology; Glyburide; Guinea Pigs; Hypertension; In Vitro Techniques; Injections, Intravenous; Male; Muscle Relaxation; Muscle, Smooth; Muscle, Smooth, Vascular; Potassium Channel Blockers; Pyrroles; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Stereoisomerism; Tolbutamide | 1994 |
K+ channel activators, acute glucose tolerance and glibenclamide-induced hypoglycaemia in the hypertensive rat.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Benzopyrans; Blood Glucose; Blood Pressure; Cromakalim; Diazoxide; Dose-Response Relationship, Drug; Glucose Tolerance Test; Glyburide; Guanidines; Hypertension; Hypoglycemia; Pinacidil; Potassium Channels; Pyrroles; Rats; Rats, Inbred SHR | 1994 |
Novel thieno[2,3-b]- and [3,4-b]pyrans as potassium channel openers. Thiophene systems--XVII.
Topics: Animals; Antihypertensive Agents; Aorta; Benzopyrans; Cromakalim; Drug Evaluation, Preclinical; Glyburide; Hypertension; In Vitro Techniques; Models, Molecular; Molecular Structure; Potassium Channels; Pyrroles; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Thiophenes | 1993 |
Pharmacodynamic behaviour of isolated resistance vessels obtained from hypertensive-diabetic rats.
Topics: Animals; Benzopyrans; Blood Glucose; Calcium Channels; Calcium Chloride; Cromakalim; Glyburide; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Methacholine Chloride; Methoxamine; Muscle Contraction; Muscle, Smooth; Nifedipine; Nitroprusside; Norepinephrine; Obesity; Potassium Channels; Potassium Chloride; Pyrroles; Rats; Rats, Zucker; Serotonin; Tunica Media; Vascular Resistance; Vasoconstrictor Agents; Vasodilator Agents | 1996 |
Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats.
Topics: Animals; Antihypertensive Agents; Benzopyrans; Blood Pressure; Cromakalim; Desoxycorticosterone; Heart Rate; Hypertension; Hypertension, Renal; Male; Potassium Channels; Pyrroles; Pyrrolidinones; Rats; Rats, Inbred SHR; Vasodilator Agents | 1998 |
Coronary revascularization and aggressive lipid lowering.
Topics: Aspirin; Atorvastatin; Coronary Stenosis; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Metoprolol; Middle Aged; Myocardial Revascularization; Plasminogen Activators; Pyrroles; Risk Factors | 1999 |
Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats.
Topics: Animals; Blood Pressure; Corticotropin-Releasing Hormone; Hypertension; Male; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Receptors, Corticotropin-Releasing Hormone | 2000 |
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
Topics: Angiotensin Receptor Antagonists; Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Culture Techniques; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; NADPH Oxidases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Vasoconstriction; Vasodilation | 2001 |
Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1b) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat.
Topics: Animals; Benzamides; Blood Pressure; Desoxycorticosterone; Dose-Response Relationship, Drug; Hypertension; In Vitro Techniques; Ketanserin; Male; Mesenteric Arteries; Phenylephrine; Potassium Chloride; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Vasoconstriction; Vasoconstrictor Agents | 2001 |
Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats.
Topics: Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Diltiazem; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley | 2001 |
Cellular antioxidant effects of atorvastatin in vitro and in vivo.
Topics: Animals; Antioxidants; Atorvastatin; Catalase; Cattle; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Muscle, Smooth, Vascular; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidases; Pyrroles; Rats; Rats, Inbred SHR; Reactive Oxygen Species; RNA, Messenger; Up-Regulation | 2002 |
Preferential small arteriolar vasodilatation by the potassium channel opener, BRL 38227, in conscious spontaneously hypertensive rats.
Topics: Animals; Arterioles; Benzopyrans; Blood Pressure; Cromakalim; Heart Rate; Hypertension; Male; Potassium Channels; Pyrroles; Rats; Rats, Inbred SHR; Vasodilation; Vasodilator Agents | 1992 |
Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
Topics: Animals; Aorta; Benzopyrans; Cromakalim; Cyclopentanes; Dihydropyridines; Dose-Response Relationship, Drug; Endothelins; Guanidines; Hypertension; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Pinacidil; Potassium Channels; Pyridines; Pyrroles; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Vasodilation; Vasodilator Agents | 1992 |
Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects.
Topics: Adult; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure; Cromakalim; Heart Rate; Humans; Hypertension; Kidney; Liver Circulation; Lung; Male; Potassium Channels; Pyrroles; Renin | 1990 |
The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Bridged Bicyclo Compounds; Half-Life; Humans; Hypertension; Pyrroles; Ramipril | 1991 |
Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine; Biphenyl Compounds; Blood Pressure; Captopril; Hypertension; Imidazoles; Kinins; Losartan; Male; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles | 1992 |
[Potassium channel activators. Perspectives in the treatment of arterial hypertension].
Topics: Antihypertensive Agents; Benzopyrans; Cromakalim; Guanidines; Humans; Hypertension; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles | 1991 |
Functional changes in potassium channels in carotid arteries from stroke-prone spontaneously hypertensive rats.
Topics: Animals; Benzopyrans; Carotid Arteries; Cerebrovascular Disorders; Cromakalim; Glyburide; Hypertension; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Norepinephrine; Potassium Channels; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 1990 |
Age-related variations in tissue angiotensin converting enzyme activities: comparison between spontaneously hypertensive and Wistar-Kyoto rats.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Binding Sites; Fluorometry; Hypertension; Peptidyl-Dipeptidase A; Pyrroles; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin-Angiotensin System | 1990 |
Variation in the aromatic ring of cromakalim: antihypertensive activity of pyranopyridines and 6-alkyl-2H-1-benzopyrans.
Topics: Animals; Antihypertensive Agents; Benzopyrans; Chemical Phenomena; Chemistry; Cromakalim; Hypertension; Pyrans; Pyridines; Pyrroles; Rats; Rats, Inbred SHR; Structure-Activity Relationship | 1990 |
Effects of cromakalim, a potassium channel opener, on regional blood flow in conscious spontaneously hypertensive rats.
Topics: Animals; Benzopyrans; Blood Pressure; Cromakalim; Heart Rate; Hemodynamics; Humans; Hypertension; Infant, Newborn; Microspheres; Nifedipine; Pyrroles; Rats; Rats, Inbred SHR; Regional Blood Flow; Vascular Resistance | 1990 |
Vascular angiotensin conversion in humans.
Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Forearm; Humans; Hypertension; Kinetics; Peptidyl-Dipeptidase A; Pyrroles; Ramipril; Reference Values; Regional Blood Flow; Renin | 1986 |
Short-term monotherapy with the potassium channel activator BRL 34915 on endocrine sodium regulation in essential hypertension.
Topics: Administration, Oral; Adult; Aldosterone; Atrial Natriuretic Factor; Benzopyrans; Blood Pressure; Cromakalim; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Pyrroles; Renin; Renin-Angiotensin System; Sodium | 1989 |
Pharmacokinetics of cromakalim--a new antihypertensive agent, in patients with mild essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Benzopyrans; Cromakalim; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hypertension; Male; Middle Aged; Pyrroles | 1989 |
Increased vasodilator responsiveness to BRL 34915 in spontaneously hypertensive versus normotensive rats: contrast with nifedipine.
Topics: Animals; Antihypertensive Agents; Aorta; Benzopyrans; Blood Pressure; Cromakalim; Dose-Response Relationship, Drug; Heart Rate; Hypertension; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Nifedipine; Phenylephrine; Pyrroles; Rats; Rats, Inbred SHR; Vascular Resistance; Vasodilation | 1989 |
Studies on the anti-vasoconstrictor activity of BRL 34915 in spontaneously hypertensive rats; a comparison with nifedipine.
Topics: Angiotensin II; Animals; Benzopyrans; Blood Pressure; Cromakalim; Dose-Response Relationship, Drug; Female; Hypertension; Infusions, Intravenous; Nifedipine; Norepinephrine; Phenylephrine; Pyrroles; Rats; Rats, Inbred SHR; Vasoconstriction; Vasopressins | 1988 |
Levels of brain angiotensin in the spontaneously hypertensive rat and treatment with ramiprilat.
Topics: Angiotensin I; Angiotensin II; Animals; Blood Pressure; Brain; Hypertension; Pyrroles; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Spinal Cord | 1986 |
[Hypertension and tachycardia in acute intermittent porphyria].
Topics: Adult; Aldosterone; Amino Acids; Anemia; Blood Pressure; Catecholamines; Depression, Chemical; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Kidney Function Tests; Levulinic Acids; Middle Aged; Porphyrias; Porphyrins; Propranolol; Pyrroles; Renin; Sympatholytics; Tachycardia; Vanilmandelic Acid | 1970 |
Hereditary coproporphyria. Photosensitivity, jaundice and neuropsychiatric manifestations associated with pregnancy.
Topics: Adolescent; Amino Acids; Epilepsy; Feces; Female; Fetal Death; Humans; Hypertension; Jaundice; Levulinic Acids; Liver Function Tests; Neurologic Manifestations; Photosensitivity Disorders; Porphyrias; Porphyrins; Postpartum Period; Pregnancy; Pregnancy Complications; Pyrroles; Skin Manifestations | 1971 |